Soki Kashima, MD, PhD
Postdoctoral Associate
Research & Publications
Biography
News
Locations
Coauthors
Selected Publications
- Update on Biomarkers in Renal Cell Carcinoma.Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.
- The Changing Landscape of Immunotherapy for Advanced Renal CancerKashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.
- Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model.Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, Numakura K, Saito M, Narita S, Yasukawa M, Ogawa O, Habuchi T, Kawamoto H. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. IScience 2020, 23: 100998. PMID: 32259478, DOI: 10.1016/j.isci.2020.100998.
- Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes.Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes. Mol Ther Methods Clin Dev 2020, 19: 250-260. PMID: 33102617, DOI: 10.1016/j.omtm.2020.09.011.
- Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. Int J Clin Oncol 2020, 25: 831-841. PMID: 31407168, DOI: 10.1007/s10147-019-01520-z.
- Prognostic impact of histological discordance between transurethral resection and radical cystectomy.Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y, Japanese Urological Oncology Group. Prognostic impact of histological discordance between transurethral resection and radical cystectomy. BJU Int 2024 PMID: 38344879, DOI: 10.1111/bju.16296.
- Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old. Int J Clin Oncol 2023, 28: 1530-1537. PMID: 37552353, DOI: 10.1007/s10147-023-02394-y.
- Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.Numakura K, Sekine Y, Hatakeyama S, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Kashima S, Yamamto R, Nara T, Akashi H, Tabata R, Sato S, Saito M, Narita S, Ohyama C, Habuchi T. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Med 2023, 12: 16837-16845. PMID: 37403728, DOI: 10.1002/cam4.6306.
- Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, Yamamoto R, Nara T, Huang M, Numakura K, Saito M, Eto M, Habuchi T. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate. Eur J Clin Pharmacol 2023, 79: 89-98. PMID: 36378297, DOI: 10.1007/s00228-022-03420-0.
- ASCO 2023 RECAP Combination Therapies Come of Age in Kidney Cancerhttps://auanews.net/issues/articles/2023/october-extra-2023/asco-2023-recap-combination-therapies-come-of-age-in-kidney-cancer
- Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab.Takahashi S, Narita S, Fujiyama N, Hatakeyama S, Kobayashi T, Kato R, Naito S, Sakatani T, Kashima S, Koizumi A, Yamamoto R, Nara T, Kanda S, Numakura K, Saito M, Obara W, Tsuchiya N, Ohyama C, Ogawa O, Habuchi T. Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab. Cancer Sci 2022, 113: 4059-4069. PMID: 35848083, DOI: 10.1111/cas.15488.
- Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Habuchi T. Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel. Int J Clin Oncol 2022, 27: 1477-1486. PMID: 35748967, DOI: 10.1007/s10147-022-02203-y.
- Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG.Inoue T, Miyake M, Nishimura N, Onozawa M, Kashima S, Numakura K, Narita S, Iida K, Uemura M, Matsushita Y, Inokuchi J, Matsui Y, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG. Urology 2022, 167: 158-164. PMID: 35700751, DOI: 10.1016/j.urology.2022.05.034.
- Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism.Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, Kashima S, Yamamoto R, Koizumi A, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes (Basel) 2022, 13 PMID: 35885987, DOI: 10.3390/genes13071204.
- Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade.Takeda M, Kashima S, Fuchigami Y, Yoshino T, Kataoka TR, Yamasaki T, Kagamu H, Kobayashi T, Akamatsu S. Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade. Front Immunol 2022, 13: 934991. PMID: 35865543, DOI: 10.3389/fimmu.2022.934991.
- [18F]FDG-labelled stem cell PET imaging in different route of administrations and multiple animal species.Nose N, Nogami S, Koshino K, Chen X, Werner RA, Kashima S, Rowe SP, Lapa C, Fukuchi K, Higuchi T. [18F]FDG-labelled stem cell PET imaging in different route of administrations and multiple animal species. Sci Rep 2021, 11: 10896. PMID: 34035416, DOI: 10.1038/s41598-021-90383-4.
- Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.Hagimoto H, Kashima S, Doi K, Nakayama S, Sano T, Imai S, Yasufuku T, Muramaki M, Yamada Y. Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. IJU Case Rep 2020, 3: 287-290. PMID: 33163928, DOI: 10.1002/iju5.12220.
- High Frequency Production of T Cell-Derived iPSC Clones Capable of Generating Potent Cytotoxic T Cells.Nagano S, Maeda T, Ichise H, Kashima S, Ohtaka M, Nakanishi M, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. High Frequency Production of T Cell-Derived iPSC Clones Capable of Generating Potent Cytotoxic T Cells. Mol Ther Methods Clin Dev 2019, 16: 126-135. PMID: 31970197, DOI: 10.1016/j.omtm.2019.12.006.
- Renal subcapsular fluid collection caused by penetration of a pancreatic pseudocyst.Kashima S, Inoue T, Chiba M, Komine N, Ito R, Numakura K, Tsuruta H, Saito M, Akihama S, Narita S, Tsuchiya N, Satoh S, Onishi H, Habuchi T. Renal subcapsular fluid collection caused by penetration of a pancreatic pseudocyst. Urology 2014, 84: e23-4. PMID: 25443952, DOI: 10.1016/j.urology.2014.07.048.